EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice: A Brazilian Multicenter Study

Leonardo Gomes da Fonseca iD, Cecília Souza Freire, Rodrigo Antonio Vieira Guedes iD, Marcos Castro Lyra, Maria Ignez Freitas Melro Braguiroli iD, Mariana Bruno Siqueira, Maria De Lourdes Lopes de Oliveira, Alexandre de Mendonça Palladino iD, Henry Luiz Najman, Rodrigo Tancredi, Duilio Reis Da Rocha Filho iD, Markus Cavalcante Gifoni iD und 5 weitere

JCO Global Oncology · 2025

DOI: 10.1200/go-25-00128 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Leonardo Gomes da Fonseca und 16 weiteren Autor:innen. Beteiligte Einrichtung: Oncologia D'Or and Instituto D'Or de Pesquisa e Ensino, São Paulo, Brazil. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Immunotherapy-based combinations have shown promising survival benefits in patients with hepatocellular carcinoma (HCC) included in clinical trials. However, real-world data are needed to assess the effectiveness and safety of these therapies in diverse clinical settings and regions. PATIENTS AND METHODS We conducted a Brazilian multicenter observational study, including 163 patients with unresectable or metastatic HCC treated with immunotherapy between August 2020 and March 2024 in 14 centers. Patient characteristics, treatment outcomes, and adverse events were analyzed. Survival outcomes were assessed using the Kaplan-Meier method, and Cox regression identified predictors of survival. RESULTS Most patients were male (85.3%), with a median age of 72 years. Liver cirrhosis was present in 70.6%, and 77% had Barcelona Clinic Liver Cancer stage C. Immunotherapy was predominantly first-line (91.4%), with atezolizumab plus bevacizumab as the most common regimen (77.9%). The median treatment duration was 4.9 months, and the median overall survival (OS) was 14.7 months (95% CI, 11.6 to 24.5), with 12- and 24-month survival rates of 57.0% and 41.4%, respectively. Considering the patients with Child-Pugh A and performance status 0-1 (n = 116), the median OS was 20.6 months (95% CI, 12.4 to 25.8). Immune-related adverse events occurred in 19.6%, mainly thyroid disorders and skin manifestations. Adverse events related to bevacizumab included variceal (n = 6) and other bleeding events (n = 7). Albumin-bilirubin grade 2 to 3, metabolic dysfunction–associated steatotic liver disease, and esophagogastric varices were independently associated with reduced OS. CONCLUSION In a real-world setting, immunotherapy-based treatments demonstrated effectiveness and safety profiles consistent with clinical trials, although survival was influenced by liver function, etiology, and baseline variceal status. These findings highlight the relevance of baseline liver disease characteristics in guiding immunotherapy in HCC and underscore the need for tailored management strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularImmunotherapyHumansMaleFemaleAgedBrazilMiddle AgedTreatment OutcomeAged, 80 and overSurvival Rate

Autor:innen und Institutionen

  • Oncologia D'Or and Instituto D'Or de Pesquisa e Ensino, São Paulo, Brazil.
  • Instituto do Cancer do Estado de São Paulo, University of São Paulo School of Medicine, São Paulo, Brazil.
  • Hospital Universitário Walter Cantídio, Universidade Federal do Ceara Fortaleza, CE, Brazil.
  • Universidade Federal da Bahia, Salvador, BA, Brazil.

ORCID-Profile: Leonardo Gomes da Fonseca, Rodrigo Antonio Vieira Guedes, Maria Ignez Freitas Melro Braguiroli, Alexandre de Mendonça Palladino, Duilio Reis Da Rocha Filho, Markus Cavalcante Gifoni, Paulo Marcelo Hoff

Zitieren

APA

da Fonseca, L. G., Freire, C. S., Guedes, R. A. V., Lyra, M. C., Braguiroli, M. I. F. M., Siqueira, M. B., de Oliveira, M. L. L., Palladino, A. M., Najman, H. L., Tancredi, R., Da Rocha Filho, D. R., Gifoni, M. C., Pereira, G. L. S., Teixeira, M. C. A., Rocha, L. S. D. S., Paraná, R., & Hoff, P. M. (2025). Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice: A Brazilian Multicenter Study. JCO Global Oncology. https://doi.org/10.1200/go-25-00128

Vancouver

da Fonseca LG, Freire CS, Guedes RAV, Lyra MC, Braguiroli MIFM, Siqueira MB, et al. Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice: A Brazilian Multicenter Study. JCO Global Oncology. 2025. doi:10.1200/go-25-00128

BibTeX
@article{daFonseca2025,
  author = {da Fonseca, Leonardo Gomes and Freire, Cecília Souza and Guedes, Rodrigo Antonio Vieira and Lyra, Marcos Castro and Braguiroli, Maria Ignez Freitas Melro and Siqueira, Mariana Bruno and de Oliveira, Maria De Lourdes Lopes and Palladino, Alexandre de Mendonça and Najman, Henry Luiz and Tancredi, Rodrigo and Da Rocha Filho, Duilio Reis and Gifoni, Markus Cavalcante and Pereira, Guilherme Luiz Stelko and Teixeira, Marcela Crosara Alves and Rocha, Lucila Soares Da Silva and Paraná, Raimundo and Hoff, Paulo Marcelo},
  title = {Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice: A Brazilian Multicenter Study},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-25-00128}
}
Kostenlos starten →